logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
Showing 1 - 20 of 70 Items
Showing 1 - 20 of 70 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Organochlorine pesticides and salinity in Karakalpakstan, Uzbekistan: Environmental health risks associated with the Aral Sea crisis

Bartrem C, Kurbanov MI, Keller BD, Fiori A, von Lindern I,  et al.
2025-11-19 • International Journal of Environmental Research and Public Health
2025-11-19 • International Journal of Environmental Research and Public Health

The legacy of Soviet-era agricultural practices in Central Asia has contributed to severe environmental degradation through residual organochlorine pesticide contamination, dramatic r...

Technical Report
|
Policy Brief

MSF in Karakalpakstan

MSF
2025-09-01
2025-09-01
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Research
Conference Material
|
Video

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Stringer B
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Slide Presentation
Conference Material
|
Poster
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, 
Journal Article
|
Research
Journal Article
|
Research
Research & Publication Resources
|
Research Protocol
Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M,  et al.
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

Rekart M, Thit P, Oluya M, Moe S, Hasan T,  et al.
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M,  et al.
2024-06-06 • Antimicrobial Agents and Chemotherapy
2024-06-06 • Antimicrobial Agents and Chemotherapy
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C,  et al.
2024-03-20 • Clinical Infectious Diseases
2024-03-20 • Clinical Infectious Diseases
BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A,  et al.
2023-05-01 • International Journal of Tuberculosis and Lung Disease
2023-05-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2022-12-22 • New England Journal of Medicine
2022-12-22 • New England Journal of Medicine
BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
Hayrapetyan A, 
et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D,  et al.
2005-10-01 • International Journal of Tuberculosis and Lung Disease
2005-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...

Factors associated with unfavorable treatment outcomes in new and previously treated TB patients in Uzbekistan: a five year countrywide study

Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P,  et al.
2015-06-15 • PLOS One
2015-06-15 • PLOS One
BACKGROUND
TB is one of the main health priorities in Uzbekistan and relatively high rates of unfavorable treatment outcomes have recently been reported. This requires closer analysi...

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N,  et al.
2020-10-10 • BMJ Open
2020-10-10 • BMJ Open
INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan

Wharton-Smith A, Horter SCB, Douch E, Gray NSB, James N,  et al.
2021-12-04 • Trials
2021-12-04 • Trials
BACKGROUND
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...